RSP - any on biologicals
32264666 2020. Childhood Rheumatic Diseases and COVID-19 Pandemic: An Intriguing Linkage and a New Horizon
32360811 ä. Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts
32256705 2020. Associations between immune-suppressive and stimulating drugs and novel COVID-19?a systematic review of current evidence
32372857 2020. COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: ?what the bleep do we know??
C7160444 ä. Use of systemic immunomodulatory therapies during the coronavirus disease 2019 (COVID-19) pandemic
32330632 ä. Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment
32335173 ä. How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review
32303756 ä. Impact of anti-tnf? antibodies on the risk of Covid-19 and its severity in patients with inflammatory Bowel Diseases
32339915 ä. Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19
32362357 ä. Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum
32314010 ä. Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs
32371550 2020. COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
32315980 2020. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
32348641 ä. Covid-19 in Immune-Mediated Inflammatory Diseases ? Case Series from New York
32348598 2020. Review article: prevention, diagnosis and management of COVID-19 in the IBD patient
32359205 2020. 2019 Novel Coronavirus Disease (COVID-19) in patients with Inflammatory Bowel Diseases
32243698 ä. Immunosuppression drug?related and clinical manifestation of Coronavirus disease 2019: A therapeutical hypothesis
32312768 2020. Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia
32241792 2020. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD
32354772 2020. Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept
32332075 2020. Patients with lupus are not protected from COVID-19
32332072 2020. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine
32295789 2020. Role of immunosuppressive therapy in rheumatic diseases concurrent with COVID-19
32327426 2020. SLE patients are not immune to covid-19: importance of sending the right message across
32295787 2020. SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment
32255510 2020. COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australian/New Zealand consensus statement
32237261 ä. The COVID?19 outbreak and rheumatologic skin diseases
32356577 2020. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration
32362061 2020. (pat.on)Dupilumab and COVID-19: What should we expect?
32354990 2020. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study
32245909 2020. A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis
32312788 2020. Covid-19 infection in Crohn s disease under treatment with adalimumab
32379925 2020. Improvement of SARS-CoV2 symptoms following Guselkumab injection in a psoriatic patient
32379913 2020. Evolution of COVID-19 infection in 4 psoriatic patients treated with biological drugs
32358791 2020. SARS-CoV-2 infection in a psoriatic patient treated with IL-17 inhibitor
32330323 2020. Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports
32294258 2020. SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor
32376395 2020. SARS-CoV-2 infection among patients with systemic autoimmune diseases
32408147 2020. Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain
32408155 2020. Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
32388458 2020. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment
32388451 2020. COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach
